Keywords
How to Cite
Abstract
A comparative study of myelotoxicity of the native antitumor drug called dioxadet administered intraperitoneally (i.p.) and during hyperthermic intraperitoneal chemoperfusion (HIPEC) in a rat model of ovarian cancer was carried out. 21 female Wistar rats with transplanted ovarian cancer were used. In 48 hours after i.p. inoculation of ovarian cancer all rats were randomized into 3 groups: I - control, i.p. administration of 0.5 ml of saline (n=7); II - single i.p. administration of dioxadet, 1.5 mg/kg of body weight (n=7); III - HIPEC with dioxadet, 15 mg/kg of body weight (n=7). I.p. administration of dioxadet caused severe prolonged leucopenia. After HIPEC with dioxadet at a dose 10 times higher compared to i.p. administration white blood cell count didn’t fall below the corresponding values in the control group. Both single i.p. injection and HIPEC with dioxadet didn’t significantly affect the change in the number of red blood cells. Trombocytopenia was registered the day after dioxadet administration in groups II and III with the rapid recovery of the platelet count to the corresponding values in the control group. As a result HIPEC with dioxadet was associated with much less myelotoxicity compared to i.p. administration of the drug.References
Беляев А.М., Багненко С.Ф., Рухляда Н.В. Внутрибрюшинная химиотерапия злокачественных опухолей брюшной полости. - СПб.: ЭЛБИ - СПб, 2007. - 254 с.
Беляева О.А., Беспалов В.Г., Сенчик К.Ю. и др. Экспериментальная технология химиоперфузионного лечения канцероматоза брюшной полости при раке яичника // Вопр. онкол. - 2014. - Т. 60, № 1. - С. 71-78.
Беспалов В.Г., Беляева О.А. , Киреева Г.С. и др. Противоопухолевое действие диоксадэта в интраперитонеальном химиоперфузионном лечении распространенного рака яичника в эксперименте // Вопр. онкол. - 2014. - Т. 60, № 2. - С. 76-80.
Беспалов В.Г., Беляева О.А., Киреева Г.С. и др. Интраперитонеальное химиоперфузионное лечение диссеминированного рака яичника диоксадэтом в сравнении с цисплатином в эксперименте // Сиб. онкол. журнал. - 2014. - Т. 62, № 2. - С. 14-18.
Гершанович М.Л., Филов В.А., Котова Д.Г. и др. Результаты кооперированного клинического изучения противоопухолевого препарата диоксадэт по II фазе // Вопр. онкол. - 1998. - Т. 44, № 2. - С. 216-220
Погосянц Е.Е., Пригожина Е.Л., Еголина Н.А. Перевиваемая асцитная опухоль яичника крысы (штамм ОЯ) // Вопр. онкол. - 1962 - Т. 8, № 11. - С. 29-36.
Стуков А.Н., Гершанович М.Л., Бланк М.А. и др. Противоопухолевые лекарственные средства. - СПб.: NIKA. - 2011. - 656 с.
Урманчеева А.Ф., Кутушева Г.Ф., Ульрих Е.А. Опухоли яичника (клиника, диагностика и лечение). - СПб.: Изд-во Н-Л. - 2012. - 68 с.
Alberts D.S., Liu P.Y., Hannigan E.V. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer // N. Engl. J. Med. - 1996. - Vol. 335. - P. 1950-1955
Armstrong D.K., Bundy B., Wenzel L. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer // N. Engl. J. Med. - 2006. - Vol. 354. - P. 34-43.
Deraco M., Baratti D., Laterza B. et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer // Eur. J. Surg. Oncol. - 2011. - Vol. 37, №1. - P. 4-9
González-Moreno S., González-Bayón L.A., Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique // World J. Gastrointest. Oncol. - 2010. - Vol. 2, № 2. - P. 68-75
Markman M., Bundy B.N., Alberts D.S. et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group // J. Clin. Oncol. - 2001. - Vol. 19. - P. 1001-1007
Ruka W., Rutkowski P., Kaminska J. et al. Alterations of routine blood tests in adult patients with soft tissue sarcomas: Relationships to cytokine serum levels and prognostic significance // Ann. Oncol. - 2001. - Vol. 12. - P. 1423-32.
Tibaldi C., Vasile E., Bernardini I. et al. Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model // J. Cancer Res. Clin. Oncol. - 2008. - Vol. 134. - P. 1143-1149.
Yue Z., Nader H., Cherif B. et al. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases // J. Gastrointest. Oncol. - 2013. - Vol. 4, № 1. - P. 62-71
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...